

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.: 91120000103100784F)
(Incorporated in the People's Republic of China)

**ANNOUNCEMENT ON THE INCREASE IN SHAREHOLDING OF S-SHARES OF THE COMPANY
BY THE CONTROLLING SHAREHOLDER AND THE PROPOSED SUBSEQUENT SHAREHOLDING
INCREASE PLAN**

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

On 5 February 2026, the Company received a notice from its controlling shareholder, Tianjin Pharmaceutical Holdings Co., Ltd. (天津市医药集团有限公司) (“TPH”), that JinYao Global Pte. Ltd. (津药国际有限公司) (“JinYao Global”)¹, a wholly-owned subsidiary of TPH, had, on 4 February 2026, acquired additional S-Shares (being ordinary shares issued by the Company to natural and legal persons in countries other than People's Republic of China, denominated in United States dollars and listed on the Singapore Exchange Securities Trading Limited (the “SGX-ST”)) through the trading system of the SGX-ST. Details of which are as set out below.

1. Acquirer

JinYao Global Pte. Ltd. (津药国际有限公司) (being a wholly-owned subsidiary of, and a party acting in concert with, TPH).

2. Information on Shareholding Increase

On 4 February 2026, JinYao Global acquired 82,200 S-Shares through the trading system of the SGX-ST at an average price of approximately US\$2.96 per S-Share, for an aggregate consideration of approximately US\$242,952.79, representing approximately 0.0107% of the total issued share capital of the Company (the “Shareholding Increase”).

The shareholding of TPH in the Company before and after the Shareholding Increase is as follows:

Shareholding	Before the Shareholding Increase	After the Shareholding Increase
No. of Shares	331,120,528	331,202,728
A-Shares	325,855,528	325,855,528
S-Shares	5,265,000	5,347,200
Shareholding	42.997%	43.008%

¹ Formerly known as Tianjin Pharmaceutical (Singapore) International Investment Pte. Ltd. (天津医药集团(新加坡)国际投资有限公司).

3. Proposed Subsequent Shareholding Increase Plan

Subsequently, arising from confidence in the Company's future development prospects and in recognition of the long-term investment value of the Company, JinYao Global proposes to further increase its shareholding of S-Shares within six (6) months from the date of the Shareholding Increase through the trading system of the SGX-ST and by means permitted under the rules of the SGX-ST (the "**Shareholding Increase Plan**").

The total number of S-Shares proposed to be acquired under the Shareholding Increase Plan (including the Shareholding Increase) shall not exceed one per cent. (1%) of the total issued share capital of the Company in any period of six (6) months.

The purchase price per S-Share proposed under the Shareholding Increase Plan shall not exceed US\$4 per S-Share (inclusive), and the total consideration (including the Shareholding Increase) proposed under the Shareholding Increase Plan shall be not less than RMB14.3 million (inclusive) and not more than RMB28.59 million (inclusive).

4. Funding Arrangement

The Shareholding Increase was funded by the internal funds of JinYao Global.

5. Undertaking by JinYao Global

During the implementation period of the Shareholding Increase Plan and within the statutory period as prescribed under applicable laws and regulations, JinYao Global undertakes not to dispose of, or otherwise reduce any of its existing shareholding in the Company.

6. Uncertainties and Risks associated with the Shareholding Increase Plan

The Shareholding Increase Plan may be subject to changes in capital market conditions or other risk factors that are currently unforeseeable, which may result in the Shareholding Increase Plan not being implemented as intended or failing to achieve the expected outcome.

The Shareholding Increase and the Shareholding Increase Plan will not affect the Company's listing status, will not result in the Company's public float failing to meet the applicable listing requirements, and will not lead to any change in the controlling shareholder of the Company or otherwise result in any change in the Company's control structure.

The Company will closely monitor the shareholding increase by TPH and its parties acting in concert in accordance with applicable laws, regulations and rules including the Listing Rules of the Shanghai Stock Exchange and the Listing Manual of the SGX-ST, and will make timely disclosures of relevant information as and when appropriate.

Shareholders and potential investors are reminded to exercise caution when dealing in the shares of the Company.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
5 February 2026